Sign up to access all valuation multiples
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
1991
3.8K+
LTM Revenue $294M
LTM EBITDA $12.5M
$7.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of December 2025, Wantai BioPharm reported last 12-month revenue of $294M and EBITDA of $12.5M.
In the same period, Wantai BioPharm achieved -$32.8M in LTM net income.
See Wantai BioPharm valuation multiples based on analyst estimatesIn the most recent fiscal year, Wantai BioPharm reported revenue of $321M and EBITDA of $53.8M.
Wantai BioPharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wantai BioPharm valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $294M | XXX | $321M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $212M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $12.5M | XXX | $53.8M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 17% | XXX | XXX | XXX |
| EBIT | -$37.6M | XXX | $0.3M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | -$32.8M | XXX | $15.2M | XXX | XXX | XXX |
| Net Margin | -11% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Wantai BioPharm has current market cap of CNY 57.0B (or $8.1B), and EV of CNY 53.5B (or $7.6B).
As of January 16, 2026, Wantai BioPharm's stock price is CNY 45 (or $6).
See Wantai BioPharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.6B | $8.1B | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialWantai BioPharm's trades at 26.0x EV/Revenue multiple, and 612.3x EV/EBITDA.
See valuation multiples for Wantai BioPharm and 15K+ public compsAs of January 16, 2026, Wantai BioPharm has market cap of $8.1B and EV of $7.6B.
Equity research analysts estimate Wantai BioPharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wantai BioPharm has a P/E ratio of -248.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.1B | XXX | $8.1B | XXX | XXX | XXX |
| EV (current) | $7.6B | XXX | $7.6B | XXX | XXX | XXX |
| EV/Revenue | 26.0x | XXX | 26.0x | XXX | XXX | XXX |
| EV/EBITDA | 612.3x | XXX | 612.3x | XXX | XXX | XXX |
| EV/EBIT | -203.2x | XXX | -203.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -248.6x | XXX | -248.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -100.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWantai BioPharm's last 12 month revenue growth is 24%
Wantai BioPharm's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Wantai BioPharm's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wantai BioPharm's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Wantai BioPharm and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | -77% | XXX | XXX | XXX |
| Rule of 40 | 53% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wantai BioPharm acquired XXX companies to date.
Last acquisition by Wantai BioPharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Wantai BioPharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Wantai BioPharm founded? | Wantai BioPharm was founded in 1991. |
| Where is Wantai BioPharm headquartered? | Wantai BioPharm is headquartered in China. |
| How many employees does Wantai BioPharm have? | As of today, Wantai BioPharm has 3.8K+ employees. |
| Is Wantai BioPharm publicy listed? | Yes, Wantai BioPharm is a public company listed on SHG. |
| What is the stock symbol of Wantai BioPharm? | Wantai BioPharm trades under 603392 ticker. |
| When did Wantai BioPharm go public? | Wantai BioPharm went public in 2020. |
| Who are competitors of Wantai BioPharm? | Similar companies to Wantai BioPharm include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Wantai BioPharm? | Wantai BioPharm's current market cap is $8.1B |
| What is the current revenue of Wantai BioPharm? | Wantai BioPharm's last 12 months revenue is $294M. |
| What is the current revenue growth of Wantai BioPharm? | Wantai BioPharm revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Wantai BioPharm? | Current revenue multiple of Wantai BioPharm is 26.0x. |
| Is Wantai BioPharm profitable? | Yes, Wantai BioPharm is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Wantai BioPharm? | Wantai BioPharm's last 12 months EBITDA is $12.5M. |
| What is Wantai BioPharm's EBITDA margin? | Wantai BioPharm's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Wantai BioPharm? | Current EBITDA multiple of Wantai BioPharm is 612.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
